Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Charles River Laboratories is a leading contract research organization (CRO) providing preclinical and clinical laboratory services for drug development. The company operates research model production facilities (primarily rodents), safety assessment laboratories across North America and Europe, and provides cell-based research tools. CRL's stock trades on biotech/pharma R&D spending cycles, with margins compressed by underutilized capacity following the post-COVID normalization in drug development activity.
CRL generates revenue through multi-year service contracts with pharmaceutical, biotech, and medical device companies conducting preclinical drug development. DSA segment operates high-fixed-cost laboratory facilities requiring specialized staff and equipment, with pricing power derived from regulatory expertise (FDA/EMA submission experience) and capacity constraints during peak demand. RMS benefits from recurring revenue as clients require continuous supply of genetically standardized research models. Gross margins of 33% reflect labor-intensive services and specialized facility requirements. Operating leverage is significant - incremental revenue drops heavily to EBITDA when facilities run above 75-80% utilization, but underutilization (currently evident in 5.6% operating margin vs historical 15-18%) severely compresses profitability.
Biotech/pharma R&D spending trends and venture capital funding for early-stage drug development (drives DSA booking rates)
DSA segment booking growth and backlog conversion rates (leading indicator of revenue 6-12 months forward)
Capacity utilization rates across toxicology laboratories (directly impacts incremental margins)
Large pharma outsourcing decisions and share shift from internal to external CRO services
M&A activity in biotech sector (consolidation reduces client count, but survivors increase outsourcing)
Technological disruption from AI-driven in-silico modeling and organ-on-chip technologies reducing demand for animal-based preclinical testing over 10+ year horizon
Regulatory pressure to reduce animal testing (EU initiatives, FDA Modernization Act 2.0) could structurally impair RMS segment and require costly facility conversions
Concentration risk in biotech sector - prolonged venture funding drought (18+ months) would force permanent capacity rationalization and facility closures
Intense competition from Laboratory Corporation (Covance), IQVIA, WuXi AppTec, and regional CROs driving pricing pressure, particularly in commoditized toxicology studies
Large pharma insourcing risk if drug pipelines shrink and internal capacity becomes underutilized (though current trend favors outsourcing)
Chinese CROs (WuXi, Pharmaron) offering 30-40% cost advantage, though geopolitical tensions and BIOSECURE Act may limit their U.S. market access
Elevated leverage at 0.77x Debt/Equity with $3.1B debt while operating margins compressed to 5.6% - limited M&A capacity until profitability recovers
Near-zero net margin (0.3%) and negative ROE (-2.5%) indicate earnings are insufficient to service debt and generate returns - requires operational turnaround
Goodwill and intangibles from historical acquisitions create impairment risk if biotech market remains depressed
high - CRL's revenue is directly tied to biotech/pharma R&D budgets, which contract sharply during risk-off environments when venture capital funding dries up and small biotech clients delay or cancel studies. Large pharma provides stability but represents minority of growth. The 1.9% revenue decline reflects post-COVID normalization as biotech funding collapsed from 2021 peaks. Economic weakness reduces IPO activity and follow-on financing, directly impacting CRL's client base ability to fund preclinical programs.
High sensitivity through two channels: (1) Rising rates devastate biotech venture funding and IPO markets, reducing CRL's client base ability to pay for services - the 2022-2023 rate hiking cycle directly caused current revenue headwinds. (2) CRL carries $3.1B debt (0.77x D/E), so rising rates increase interest expense, though much is fixed-rate. (3) Higher discount rates compress CRL's valuation multiple (currently 20x EV/EBITDA vs. historical 15-17x). Rate cuts would stimulate biotech funding and improve client liquidity.
Moderate - CRL extends payment terms to biotech clients, creating accounts receivable risk when small biotechs fail (elevated in current environment). However, large pharma clients (40%+ of revenue) have minimal credit risk. Tightening credit conditions reduce biotech access to capital, forcing study cancellations and payment delays. CRL's 1.37x current ratio provides adequate liquidity buffer.
value - Currently trading at depressed multiples (2.0x P/S vs. historical 3.5-4.5x) due to cyclical trough in biotech funding. Attracts value investors betting on mean reversion as interest rates decline and biotech funding recovers. The 6.3% FCF yield despite margin compression indicates strong cash generation potential. Not a growth stock given -1.9% revenue decline and -97.8% earnings decline, but offers cyclical recovery optionality.
high - Stock exhibits high beta to biotech sector sentiment and interest rate expectations. The -4.6% 3-month return despite +5.3% 1-year return shows significant volatility. Earnings volatility is extreme (97.8% decline) due to operating leverage. Institutional ownership is high, but sentiment shifts rapidly based on biotech funding data and Fed policy expectations.
